{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:33:10Z","timestamp":1769041990418,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"BMS, New York City, New York, Unites States of America","award":["BMS Protocol ID:IM047-036"],"award-info":[{"award-number":["BMS Protocol ID:IM047-036"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40120-025-00831-w","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:24:45Z","timestamp":1759937085000},"page":"2583-2604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Selective S1P Receptor Modulation in Multiple Sclerosis Alters CXCL13:CXCR5-Associated Immune Activities Without Impacting Anti-SARS-CoV-2 Immunity"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7717-6125","authenticated-orcid":false,"given":"Andrea","family":"Harrer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5704-9097","authenticated-orcid":false,"given":"Richard F.","family":"Radlberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Buchegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke","family":"Slade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Haybaeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannes","family":"Oberkofler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin E.","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinand","family":"Otto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wipfler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"Pt 6","key":"831_CR1","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/brain\/123.6.1174","volume":"123","author":"A Bitsch","year":"2000","unstructured":"Bitsch A. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain. 2000;123(Pt 6):1174\u201383.","journal-title":"Brain"},{"issue":"4","key":"831_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/bpa.12841","volume":"30","author":"C Reali","year":"2020","unstructured":"Reali C, et al. B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis. Brain Pathol. 2020;30(4):779\u201393.","journal-title":"Brain Pathol"},{"issue":"Pt 9","key":"831_CR3","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/brain\/awr182","volume":"134","author":"OW Howell","year":"2011","unstructured":"Howell OW, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011;134(Pt 9):2755\u201371.","journal-title":"Brain"},{"issue":"Pt 4","key":"831_CR4","first-page":"1089","volume":"130","author":"R Magliozzi","year":"2007","unstructured":"Magliozzi R, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130(Pt 4):1089\u2013104.","journal-title":"Brain"},{"issue":"5","key":"831_CR5","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ana.27034","volume":"96","author":"A Scalfari","year":"2024","unstructured":"Scalfari A, et al. Smouldering-associated worsening in multiple sclerosis: an international consensus statement on definition, biology, clinical implications, and future directions. Ann Neurol. 2024;96(5):826\u201345.","journal-title":"Ann Neurol"},{"issue":"3","key":"831_CR6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/ana.25786","volume":"88","author":"R Magliozzi","year":"2020","unstructured":"Magliozzi R, et al. The CSF profile linked to cortical damage predicts multiple sclerosis activity. Ann Neurol. 2020;88(3):562\u201373.","journal-title":"Ann Neurol"},{"issue":"4","key":"831_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","volume":"41","author":"S Crotty","year":"2014","unstructured":"Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41(4):529\u201342.","journal-title":"Immunity"},{"issue":"5","key":"831_CR8","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","volume":"50","author":"S Crotty","year":"2019","unstructured":"Crotty S. T follicular helper cell biology: a decade of discovery and diseases. Immunity. 2019;50(5):1132\u201348.","journal-title":"Immunity"},{"issue":"2","key":"831_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/ni.3054","volume":"16","author":"H Ueno","year":"2015","unstructured":"Ueno H, Banchereau J, Vinuesa CG. Pathophysiology of T follicular helper cells in humans and mice. Nat Immunol. 2015;16(2):142\u201352.","journal-title":"Nat Immunol"},{"key":"831_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626199","volume":"12","author":"TS Tyllis","year":"2021","unstructured":"Tyllis TS, et al. CXCR5(+)CD8(+) T cells shape antibody responses in vivo following protein immunisation and peripheral viral infection. Front Immunol. 2021;12:626199.","journal-title":"Front Immunol"},{"issue":"176","key":"831_CR11","doi-asserted-by":"publisher","first-page":"176ra32","DOI":"10.1126\/scitranslmed.3005191","volume":"5","author":"SE Bentebibel","year":"2013","unstructured":"Bentebibel SE, et al. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med. 2013;5(176):176ra32.","journal-title":"Sci Transl Med"},{"issue":"1","key":"831_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.immuni.2010.12.012","volume":"34","author":"R Morita","year":"2011","unstructured":"Morita R, et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011;34(1):108\u201321.","journal-title":"Immunity"},{"key":"831_CR13","volume":"1","author":"E Alvarez","year":"2015","unstructured":"Alvarez E, et al. Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures. Mult Scler J. 2015;1:2055217315623800.","journal-title":"Mult Scler J"},{"issue":"1","key":"831_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/1352458516639384","volume":"23","author":"L Novakova","year":"2017","unstructured":"Novakova L, et al. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Mult Scler. 2017;23(1):62\u201371.","journal-title":"Mult Scler"},{"key":"831_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104425","volume":"69","author":"D Baker","year":"2023","unstructured":"Baker D, et al. The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination. Mult Scler Relat Disord. 2023;69:104425.","journal-title":"Mult Scler Relat Disord"},{"issue":"24","key":"831_CR16","doi-asserted-by":"publisher","first-page":"21453","DOI":"10.1074\/jbc.C200176200","volume":"277","author":"V Brinkmann","year":"2002","unstructured":"Brinkmann V, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277(24):21453\u20137.","journal-title":"J Biol Chem"},{"issue":"19","key":"831_CR17","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","volume":"97","author":"S Simpson-Yap","year":"2021","unstructured":"Simpson-Yap S, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97(19):e1870\u201385.","journal-title":"Neurology"},{"key":"831_CR18","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200021","author":"S Simpson-Yap","year":"2022","unstructured":"Simpson-Yap S, et al. Updated results of the COVID-19 in MS global data sharing initiative: anti-CD20 and other risk factors associated with COVID-19 severity. Neurol Neuroimmunol Neuroinflamm. 2022. https:\/\/doi.org\/10.1212\/NXI.0000000000200021.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"831_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104102","volume":"81","author":"X Wu","year":"2022","unstructured":"Wu X, et al. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: a meta-analysis. EBioMedicine. 2022;81:104102.","journal-title":"EBioMedicine"},{"issue":"2","key":"831_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373.","journal-title":"Lancet Neurol"},{"key":"831_CR21","unstructured":"WorldHealthOrganisation. Coronavirus disease (COVID-19) pandemic. 23 June 2025, at 16:17 (MEZ). https:\/\/www.who.int\/europe\/emergencies\/situations\/CoVid-19. Accessed 23 June 2025."},{"issue":"5","key":"831_CR22","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.4049\/jimmunol.1900955","volume":"204","author":"JE Huber","year":"2020","unstructured":"Huber JE, et al. Fingolimod profoundly reduces frequencies and alters subset composition of circulating T follicular helper cells in multiple sclerosis patients. J Immunol. 2020;204(5):1101\u201310.","journal-title":"J Immunol"},{"issue":"12","key":"831_CR23","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1172\/JCI76861","volume":"124","author":"PT Sage","year":"2014","unstructured":"Sage PT, et al. Circulating t follicular regulatory and helper cells have memory-like properties. J Clin Investig. 2014;124(12):5191\u2013204.","journal-title":"J Clin Investig"},{"issue":"4","key":"831_CR24","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.immuni.2013.08.031","volume":"39","author":"M Locci","year":"2013","unstructured":"Locci M, et al. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity. 2013;39(4):758\u201369.","journal-title":"Immunity"},{"issue":"4","key":"831_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.immuni.2013.09.011","volume":"39","author":"N Schmitt","year":"2013","unstructured":"Schmitt N, Ueno H. Blood Tfh cells come with colors. Immunity. 2013;39(4):629\u201330.","journal-title":"Immunity"},{"key":"831_CR26","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000839","author":"S Harris","year":"2020","unstructured":"Harris S, et al. Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS. Neurol Neuroimmunol Neuroinflamm. 2020. https:\/\/doi.org\/10.1212\/NXI.0000000000000839.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"831_CR27","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/art.42446","volume":"75","author":"JS Gofshteyn","year":"2023","unstructured":"Gofshteyn JS, et al. Association of juvenile dermatomyositis disease activity with the expansion of blood memory B and T cell subsets lacking follicular markers. Arthritis Rheumatol. 2023;75(7):1246\u201361.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"831_CR28","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1073\/pnas.1520112113","volume":"113","author":"C Havenar-Daughton","year":"2016","unstructured":"Havenar-Daughton C, et al. CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad Sci USA. 2016;113(10):2702\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"831_CR29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s15010-021-01598-6","volume":"49","author":"V Gl\u00fcck","year":"2021","unstructured":"Gl\u00fcck V, et al. Sars-cov-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19. Infection. 2021;49(4):739\u201346.","journal-title":"Infection"},{"issue":"11","key":"831_CR30","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang D, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061\u20139.","journal-title":"JAMA"},{"key":"831_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102073","volume":"39","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G, et al. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord. 2020;39:102073.","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"831_CR32","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1600-6143.2004.00476.x","volume":"4","author":"V Brinkmann","year":"2004","unstructured":"Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant. 2004;4(7):1019\u201325.","journal-title":"Am J Transplant"},{"issue":"11","key":"831_CR33","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","volume":"18","author":"G Comi","year":"2019","unstructured":"Comi G, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18(11):1009\u201320.","journal-title":"Lancet Neurol"},{"issue":"11","key":"831_CR34","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","volume":"18","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18(11):1021\u201333.","journal-title":"Lancet Neurol"},{"issue":"8","key":"831_CR35","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/jcph.887","volume":"57","author":"JQ Tran","year":"2017","unstructured":"Tran JQ, et al. Results from the first-in-human study with Ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator. J Clin Pharmacol. 2017;57(8):988\u201396.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"831_CR36","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1007\/s10620-024-08391-z","volume":"69","author":"S Harris","year":"2024","unstructured":"Harris S, et al. Ozanimod differentially impacts circulating lymphocyte subsets in patients with moderately to severely active Crohn\u2019s disease. Dig Dis Sci. 2024;69(6):2044\u201354.","journal-title":"Dig Dis Sci"},{"issue":"11","key":"831_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002685","volume":"15","author":"M Warny","year":"2018","unstructured":"Warny M, et al. Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. PLoS Med. 2018;15(11):e1002685.","journal-title":"PLoS Med"},{"issue":"10","key":"831_CR38","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/acn3.51862","volume":"10","author":"BAC Cree","year":"2023","unstructured":"Cree BAC, et al. SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis. Ann Clin Transl Neurol. 2023;10(10):1725\u201337.","journal-title":"Ann Clin Transl Neurol"},{"key":"831_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577065","volume":"337","author":"M K\u00fcrt\u00fcnc\u00fc","year":"2019","unstructured":"K\u00fcrt\u00fcnc\u00fc M, et al. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients. J Neuroimmunol. 2019;337:577065.","journal-title":"J Neuroimmunol"},{"issue":"10","key":"831_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111115","volume":"9","author":"N Claes","year":"2014","unstructured":"Claes N, et al. Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study. PLoS ONE. 2014;9(10):e111115.","journal-title":"PLoS ONE"},{"issue":"5","key":"831_CR41","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s41590-022-01175-5","volume":"23","author":"KM Wragg","year":"2022","unstructured":"Wragg KM, et al. Establishment and recall of SARS-CoV-2 spike epitope-specific CD4(+) T cell memory. Nat Immunol. 2022;23(5):768\u201380.","journal-title":"Nat Immunol"},{"issue":"7","key":"831_CR42","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1084\/jem.20161794","volume":"214","author":"A Heit","year":"2017","unstructured":"Heit A, et al. Vaccination establishes clonal relatives of germinal center T cells in the blood of humans. J Exp Med. 2017;214(7):2139\u201352.","journal-title":"J Exp Med"},{"issue":"9","key":"831_CR43","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/jnnp-2022-329395","volume":"93","author":"L Meyer-Arndt","year":"2022","unstructured":"Meyer-Arndt L, et al. SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod. J Neurol Neurosurg Psychiatry. 2022;93(9):960\u201371.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"831_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100640","volume":"3","author":"K van der Ploeg","year":"2022","unstructured":"van der Ploeg K, et al. TNF-\u03b1(+) CD4(+) T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. Cell Rep Med. 2022;3(6):100640.","journal-title":"Cell Rep Med"},{"issue":"3","key":"831_CR45","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/blood-2013-02-483586","volume":"122","author":"M Frentsch","year":"2013","unstructured":"Frentsch M, et al. CD40L expression permits CD8+ T cells to execute immunologic helper functions. Blood. 2013;122(3):405\u201312.","journal-title":"Blood"},{"key":"831_CR46","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3389\/fnins.2019.01026","volume":"13","author":"Z Bai","year":"2019","unstructured":"Bai Z, et al. Cerebrospinal fluid and blood cytokines as biomarkers for multiple sclerosis: a systematic review and meta-analysis of 226 studies with 13,526 multiple sclerosis patients. Front Neurosci. 2019;13:1026.","journal-title":"Front Neurosci"},{"issue":"1","key":"831_CR47","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1038\/s41598-025-85650-7","volume":"15","author":"J Zhou","year":"2025","unstructured":"Zhou J, et al. Analysis of changes in the chemokine CXC ligand 13 in serum and cerebrospinal fluid of patients with neuromyelitis optica. Sci Rep. 2025;15(1):2113.","journal-title":"Sci Rep"},{"key":"831_CR48","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200050","author":"N Fissolo","year":"2023","unstructured":"Fissolo N, et al. Serum levels of CXCL13 are associated with teriflunomide response in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023. https:\/\/doi.org\/10.1212\/NXI.0000000000200050.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"831_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.796482","volume":"12","author":"M Iannetta","year":"2021","unstructured":"Iannetta M, et al. B- and T-cell responses after SARS-CoV-2 vaccination in patients with multiple sclerosis receiving disease modifying therapies: immunological patterns and clinical implications. Front Immunol. 2021;12:796482.","journal-title":"Front Immunol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00831-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00831-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00831-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T12:04:27Z","timestamp":1763381067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00831-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["831"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00831-w","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrea Harrer received travel support from BMS and honoraria for lectures from Merck. Richard F Radlberger received travel support, honoraria for presentations or participation on advisory boards from Bristol-Myers Squibb, Novartis, Merz Pharma, AbbVie, Sanofi Genzyme, A-med, Biogen, Merk, Ipsen Pharma, AOP Orphan Pharmaceuticals, STADA, Medtronic and L\u00f6wenstein Medical. Beate Buchegger, Brooke Slade, Thomas Haybaeck, Hannes Oberkofler, Konstantin E Thiel has nothing to disclose. Ferdinand Otto received speakers honoraria or travel support from Biogen, BMS, Merck, Novartis, Roche, Sanofi-Genzyme, Teva-Ratiopharm. Tobias Moser received travel support, honoraria for presentations or participation on advisory boards from Biogen, BMS, Novartis, Roche, Sanofi, Merck, Stada and Teva. Peter Wipfler has received personal honoraria for lectures and educational activities from Alexion, Biogen, Merck, Neuraxpharm, Novartis, Roche, Sanofi-Genzyme, Teva-Ratiopharm, Janssen-Pharmazeutika, Bristol-Myers SQUIBB and Horizon Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All patients and healthy probands provided written informed consent for participation in non-interventional biomedical basic research in MS and clinically isolated syndrome approved by the local ethics committee of the Bundesland Salzburg (415-E\/1612\/11-2018). The study was carried out according to the Helslinki protocol in its current version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}